MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

JNJ-38158471

CAS No. : 951151-97-6

MCE 站：JNJ-38158471

产品活性：JNJ-38158471 是一种耐受良好，有口服活性的高选择性 VEGFR-2 抑制剂，IC₅₀ 值为 40 nM。JNJ-38158471 还抑制 Ret 和 Kit ，IC₅₀ 值分别为 180 和 500 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：VEGFR  |  RET  |  c-Kit

In Vitro: JNJ-38158471 (1-500 nM; 1 hour) inhibits VEGF-stimulated VEGFR-2 autophosphorylation in HUVECs.
JNJ-38158471 (50-1000 nM; 12-16 hours) signi?cantly inhibits VEGF-dependent HUVEC migration. Cellular toxicity is not observed following JNJ-38158471 treatment of HUVECs.

In Vivo: JNJ-38158471 (10 or 100 mg/kg; p.o.; once-daily) inhibits VEGF-induced corneal neovascularization.
JNJ-38158471 (10-200 mg/kg; p.o.) inhibits the growth of human tumor xenografts in a dose-dependent manner in both A431 and HCT116 models. JNJ-38158471 treatment is well tolerated, following continuous administration for 24 days, body weights were comparable with control animals.
JNJ-38158471 (100 mg/kg; p.o.; once-daily) treatment shows statistically signi?cant activity compare with vehicle treat animals. The body weights of both JNJ-38158471-treated and vehicle-treated groups were comparable at study end.

相关产品：Sorafenib  |  Pexidartinib  |  Lenvatinib  |  Nintedanib  |  Regorafenib  |  Cabozantinib  |  Bevacizumab  |  Sunitinib  |  Ponatinib  |  Semaxinib  |  Imatinib  |  Axitinib  |  Pralsetinib  |  Pazopanib  |  Vandetanib  |  SU 5402  |  Avapritinib  |  Selpercatinib  |  PD173074  |  Ripretinib  |  Cediranib  |  RAF265  |  Foretinib  |  5Z-7-Oxozeaenol  |  Tivozanib  |  Gandotinib  |  Lucitanib

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。